Objective To evaluate the efficacy and safety of bortezomib-based vs non-bortezomib-based
post-transplantation therapy in patients with multiple myeloma. Methods Data of relevant …

The efficacy and safety of single-agent bortezomib or bortezomib-based regimens as
consolidation therapy after autologous hematopoietic stem cell transplantation (ASCT) in …

Abstract Background/Aims: The incorporation of bortezomib into the chemotherapeutic
regimens for non-transplant patients with multiple myeloma resulted in improved outcomes …

Comprehensive recommendations for maintenance therapy after autologous stem cell
transplantation (ASCT) for patients with multiple myeloma (MM) have yet to be defined …

Although multiple myeloma remains an incurable disease, its management has changed
recently with the introduction of novel agents, including bortezomib. Several pilot studies …

Abstract Background The Japan Study Group for Cell Therapy and Transplantation (JSCT)
organized a phase II study to evaluate the efficacy and safety of a treatment protocol (JSCT …

We conducted a systematic review to determine the appropriate use of bortezomib alone or
in combination with other agents in patients with multiple myeloma (MM). We searched …

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of
bortezomib-melphalan-prednisone as initial treatment for autologous stem cell …

Background A majority of multiple myeloma (MM) patients fail to achieve complete response
(CR) to peripheral blood stem cell transplantation (PBSCT); effective options following …

Multiple myeloma (MM) is an incurable disease with a poor survival, which has not been
affected even by high-dose chemotherapy. This systematic review was performed to assess …